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Abstract: Aripiprazole is a third generation atypical antipsychotic with compelling evidence 
as a highly effective treatment option in the management of acute manic and mixed episodes 
of bipolar I disorders. It has a unique mode of action, acting as a partial agonist at dopamine 
D2 and D3, and serotonin 5-HT1A; and exhibiting antagonistic action at the 5-HT2A and H1 
  receptors. Overall, it has a favorable safety and tolerability profile, with low potential for clini-
cally significant weight gain and metabolic effects, especially compared to other well-established 
treatments. It also has a superior tolerability profile when used as maintenance treatment. Side 
effects like headache, insomnia, and extrapyramidal side effects (EPSEs), such as tremor and 
akathisia may be treatment limiting in some cases. It is efficacious in both acute mania and mixed 
states, and in the long-term prevention of manic relapses. Aripiprazole therefore, is a significant 
player in the current portfolio of anti-manic pharmacological treatments. The data sources for 
this article are from EMBASE, MEDLINE, and the clinical trial database searches for all the 
literature published between January 2003 and September 2013. The key search terms were 
“aripiprazole” combined with “bipolar disorder”, “mania”, “antipsychotics”, “mood stabilizer”, 
“randomized controlled trial”, and “pharmacology”. Abstracts and proceedings from national 
and international psychiatric meetings were also reviewed, along with reviews of the reference 
lists of relevant articles.
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Introduction
Bipolar disorder (BD) is a life-long and life-threatening illness, with a 12-month 
prevalence of 2.8%, and contributed £342 million to the direct costs of the National 
Health Service in the UK in 2009.1
The full spectrum of BD consists of bipolar I and II disorders, cyclothymic   disorder, 
substance/medication-induced bipolar and related disorder, bipolar and related dis-
order due to another medical condition, other specified bipolar and related disorder, 
and unspecified bipolar and related disorder (eg, hypomanic episodes not fulfilling 
time or symptom severity criteria, isolated hypomanic episode(s) without depression, 
or cyclothymia falling short of the time criterion of 24 months, etc). Mixed episodes 
which previously constituted a bipolar I subcategory on its own, are now described in 
the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM5) as 
a specifier “with mixed features” which can now be applied to mania, hypomania, or 
depression.2 Traditional cornerstones of the pharmacological treatment of BD have been 
lithium (LI) and some mood-stabilizing anticonvulsants, ie, carbamazepine, valproate 
(VAL), and lamotrigine. For the depressive phase of BD, antidepressants are widely Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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used, though their effectiveness remains controversial.3 In the 
last decade, however, second and third generation antipsy-
chotics (SGA, TGA) have emerged as novel treatments for 
BD. Meanwhile, they are considered as standard treatment 
for mania4 and maintenance,5 and in the case of quetiapine, 
also for bipolar depression.6
Similar to the SGA, the TGA aripiprazole (ARI) was 
successfully tested in schizophrenia7 before pivotal studies 
in acute mania were conducted. Together with subsequent 
continuation and maintenance studies, we now have a very 
reasonable portfolio at hand that supports ARI effectiveness 
in BD. After reviewing the unique pharmacological profile 
of ARIs, this article will give a critical appraisal of the study 
portfolio, and considering additional aspects such as safety, 
tolerability, and impact on patient’s quality of life, suggest 
an appropriate placement of aripiprazole in a modern bipolar 
treatment algorithm.
Pharmacology of aripiprazole
Pharmacodynamic data
ARI is a partial agonist of dopamine D2/D3 and serotonin 
5-HT1A receptors with modest antagonistic effects at 
5-HT2A, 5-HT7, histamine H1 receptors, and moderate 
inhibitory action on serotonin reuptake.8–13 It blocks the 
occupancy of endogenous dopamine to its receptors and at 
the same time leads to partial dopamine receptor activation. 
This leaves 25%–30% of the maximal dopamine activity in 
the presence of ARI.14 A recent study showed the effects of 
ARI in stabilizing dopamine synthesis capacity.15 Its active 
metabolite, dehydro-aripiprazole, which has similar proper-
ties to the parent drug, contributes towards the overall effect.16 
The net effects are a reduction of the overall transmission 
of dopamine in hyperdopaminergic regions of the brain, but 
unlike an antagonist, also a low tonic action in mesocortical 
areas. It also has moderate affinity for Alpha 1 –   adrenergic 
and H1 receptors and negative affinity for muscarinic 
receptors. This may explain the lower risk associated with 
its use in the context of weight gain, sedation, and orthos-
tatic hypotension.17,18 Its potential for QTc prolongation is 
comparable to that of placebo (PLB).19
Pharmacokinetic data
ARI is available in oral (tablet or liquid) and intramuscular 
(IM) formulations. It is well absorbed, with an oral bioavail-
ability of 87%, and can be taken without regards to food. 
It is highly protein bound, mainly to albumin (.99%).12,19 
It shows linear pharmacokinetics20,21 at therapeutic doses 
with peak plasma concentrations reached between 3–5 
hours after ingestion and has a significantly longer half-life 
of 75 hours in comparison to other antipsychotics. This 
offers an advantage to patients in maintaining therapeutic 
blood levels in case they forget to take their medication in 
the short term. Steady state concentrations are achieved 
within 14 days of administration. When ARI injections were 
administered IM to healthy subjects, the median times to the 
peak plasma concentrations were 1 hour and 3 hours, with 
a 100% bioavailability being on average 19% higher than 
the maximum contration (Cmax) of the oral tablet.12,20
ARI is extensively metabolized in the liver by dehydroge-
nation and hydroxylation by cytochrome P450 CYP2D6 and 
N-dealkylation by cytochrome CYP3A4.12,19 It also does not 
induce or inhibit CYP2D6 or CYP3A4 enzymes and it does 
not influence the pharmacokinetics of VAL or LI.21 However, 
inducers or inhibitors of these enzymes will lead to a cor-
responding decrease or increase in plasma concentration of 
ARI.22 Poor metabolizers of CYP2D6 substrates (about 8% 
of Caucasians), have about 80% higher exposure to ARI 
and about 30% lower exposure to dehydro-ARI, resulting in 
approximately 60% higher exposure to total active drug.12 
Additionally, the elimination half-life is doubled (146 versus 
[vs] 75 hours) in poor metabolisers.12,19
Of those psychotropic medications which might be used 
in addition to ARI, only a few are prone to interactions. 
Through CYP 3A4 inhibition or induction, respectively, 
fluvoxamine could increase ARI serum levels, whereas car-
bamazepine will decrease ARI levels. In animal experiments, 
combined fluvoxamine and ARI resulted in hepatic damage.23 
Duloxetine has been described as a moderate inhibitor of 
CYP2D6. However, coadministration of duloxetine and 
ARI does not seem to result in significant pharmacological 
or clinical adverse effects.24
What often seems to attract less attention when discuss-
ing pharmacokinetic interactions is the major human hepatic 
hydrolase, carboxylesterase 1 (hCES1), that serves as a 
target of metabolic inhibition by a variety of medications. 
Besides perphenazine, thioridazine, and fluoxetine, ARI 
was determined to be a potent hCES1 inhibitor. In mice, 
coadministration of ARI with the hCES1 substrate meth-
ylphenidate (MPH), commonly used in ADHD, but also 
treatment refractory depression, resulted in significantly 
increased MPH levels.25 So far, there have been no reports 
of this specific interaction in humans, but clinicians should 
be aware of this risk. Clinical signs of MPH intoxication 
usually include mydriasis, tremor, agitation, hyperreflexia, 
combative behavior, confusion, hallucinations, delirium, 
anxiety, paranoia, movement disorders, and seizures.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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Acute manic phase studies
ARI has been extensively studied in acute bipolar mania; 
selected studies are depicted in Table 1. The latest study 
of ARI in acute mania was a multi-center double-blind 
trial of Asian patients (Japan) that investigated the efficacy 
and safety of ARI (24 mg/day) versus PLB for 3 weeks. 
  Statistically significant mean improvements were noted 
from day 4 onwards to week 3 (−11.3 vs −5.3 on the Young 
Mania Rating Scale [YMRS] at endpoint; last observation 
carried forward [LOCF] analysis).26 These results are in line 
with two earlier pivotal trials of ARI 30 mg versus PLB 
conducted mainly in Caucasian populations.27,28 However, 
a further study comparing two fixed doses of ARI (15 mg, 
30 mg) versus PLB in acutely relapsed, hospitalized patients 
did not show statistically significant separation of scores 
between the PLB and treatment groups. This was attributed 
to the unexpectedly high PLB response rate.29
A 30-week pediatric randomized controlled trial (RCT) 
compared ARI vs PLB for its acute anti-manic effects 
at 4 weeks30 and its efficacy in the continuation phase at 
30 weeks.31 It showed that both doses of ARI used, ie, 10 mg 
and 30 mg, had superior anti-manic effects and had longer 
continuation times than PLB at both endpoints. In a well-
powered trial, both ARI and haloperidol (HAL) showed a 
significantly greater mean change in the YMRS compared 
to PLB at 3 weeks with comparable improvements at 
12 weeks.32 In another study comparing ARI, LI, and PLB 
(1:1:1 randomization) for 3- and 12-week periods, ARI 
showed significant improvement in the mean YMRS score 
within 2 days. This improvement continued over 3 weeks 
and was sustained over 12 weeks, with a similar magnitude 
for both drugs.33
A randomized comparator trial against HAL and without 
a PLB arm found ARI being even more efficacious than HAL; 
however, this study was putting more weight on tolerability 
than efficacy and may not constitute a fair comparison.34 
Finally, a small study comparing subjects on ARI versus 
  olanzapine showed comparable changes in YMRS from base-
line to day 15 in both groups without the need for increasing 
the dose of benzodiazepines in the ARI group.35 In summary, 
all the trials comparing ARI (doses of 15–30 mg) to estab-
lished standard treatments showed comparable anti-manic 
efficacy, with an early and continued separation from PLB 
in YMRS scores and remission rates at 3 and 12 weeks, but 
with lower dropout rates in subjects taking ARI.
In an IM ARI study for the treatment of agitation in 
patients with bipolar I disorder, manic, or mixed episodes, 
subjects were randomized to four equally sized groups 
(about 75 each of IM ARI 9.75 mg, IM ARI 15 mg, IM 
  lorazepam 2 mg, and IM PLB). Mean improvements in 
PANSS (Positive and Negative Syndrome Scale) Excited 
Component score at 2 hours were significantly greater with 
IM ARI (9.75 mg, −8.7; 15 mg, −8.7) and IM lorazepam 
(−9.6) versus IM PLB (−5.8; P#0.001). Both IM ARI 
doses were well tolerated; the safety profile was similar to 
oral ARI.36
Finally, ARI has demonstrated additional benefits adjunc-
tive to LI or VAL in acute mania. Acutely manic patients 
partially non-responsive to MS alone and receiving combined 
treatment with ARI and one of the MS had a significantly 
higher reduction of their baseline YMRS score at week 6 
(at study endpoint: −13.3 for ARI, −10.7 for PLB). Similar 
to the monotherapy studies, significant improvement in the 
YMRS total score with ARI versus PLB was observed from 
week 1 onward.37
Continuation phase studies
The 12-week acute phase study34 comparing ARI and LI 
was followed by a 40-week continuation phase study. ARI 
monotherapy was equally useful compared to LI for the 
prevention of manic and mixed episode relapses, and had a 
similar time to discontinuation as well as time to relapse.38 
Another study (n=337) evaluated the efficacy and safety of 
ARI adjunctive to LI or VAL (ARI+LI  /  VAL) compared with 
PLB adjunctive to LI or VAL (PLB+LI  /  VAL) for patients with 
bipolar I disorder who had an inadequate response to LI or 
VAL monotherapy at week 12 of the study. At week 52, the 
combination of ARI with the mood stabilizers (MS) was more 
favorable with a hazard ratio (HR) of 0.54 (95% confidence 
interval [CI]: −0.33 to 0.89; log-rank P=0.014 [Kaplan–Meier 
relapse rate]). These findings suggest that there is benefit in 
continuing the ARI adjunctive to an MS after response to 
the acute phase treatment has been achieved.39 In a 52-week 
study, completers of a 6-week double-blind comparison of 
adjunctive ARI versus PLB in bipolar mania only partially 
responsive to LI or VAL monotherapy could enter a 46-week 
extension treatment with open-label adjunctive ARI plus LI 
(ARI+LI) or VAL (ARI+VAL). Significant improvements 
from baseline over the 52 weeks (LOCF) occurred with 
ARI+LI and ARI+VAL on the mean (95% CI) YMRS total 
score (−16.5 [−18.1; −14.8] and −17.6 [−18.9; −16.3], both 
P,0.001 vs baseline) and Montgomery–Åsberg Depres-
sion Rating Scale (MADRS) total score (−1.7 [−3.3; −0.1], 
P,0.05 vs baseline vs −2.7 [−4.0; −1.4], P,0.001 vs 
baseline).40 In a study evaluating the efficacy and safety of 
ARI plus lamotrigine (LTG) (n=178) compared with PLB Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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Aripiprazole in mania
plus LTG (n=173), the dual drug combination led to delay 
in the time to manic/mixed relapse which, however, did not 
reach statistical significance at week 52 (HR: 0.55; 95% CI: 
0.30–1.03; P=0.058).41
Maintenance study
A 26-week, double-blind, PLB-controlled relapse preven-
tion study of ARI42 was followed by a prospective, 74-week, 
double-blind, PLB-controlled extension phase. Patients 
who achieved stabilization in the initial study continued for 
a further 74 weeks. At 100 weeks, the time to relapse was 
significantly longer with ARI (N=7) than PLB (N=5; HR: 
0.53; 95% CI: 0.32–0.87; P=0.011). ARI was superior to 
PLB in delaying time to a manic relapse (HR: 0.35; 95% 
CI: 0.16–0.75; P=0.005). The initial continuation treatment 
over 26 weeks demonstrated that ARI was effective for 
relapse prevention in patients who were initially stabilized 
with ARI for 6 consecutive weeks. However, between week 
26 and 100, no further separation of survival curves for ARI 
and PLB occurred; thus, the study did not demonstrate a true 
long-term prophylactic effect of ARI. In addition, all conclu-
sions from outcome data at week 100 were severely limited 
by the high attrition rate.43
Meta-analysis  
and systematic reviews
This section focuses on the meta-analyses comparing the 
efficacy of ARI versus PLB or other comparators. The meta-
analyses of ARI monotherapy in acute mania by Fountoulakis 
et al44 (n=2,303) included six trials which assessed the effi-
cacy of ARI against acute manic/mixed episodes. ARI was 
superior compared to PLB or the comparator (HAL) in three 
of these studies. ARI was equally efficacious to comparators, 
ie, LI, HAL, and better than PLB in the other two studies. The 
pooled effect size at week 3 for ARI versus PLB was 0.34. 
ARI had an NNT of 6 for response at 3 weeks and 12 for 
response at 12 weeks. NNT for remission at 3 and 12 weeks 
were 14 and 10, respectively.44 In an earlier review includ-
ing six trials and looking into the use of ARI for psychotic 
symptoms in BD, the overall effect sizes for PANSS score 
reduction was 0.18, with greater effect sizes for the posi-
tive subscale (0.28) and the hostility subscale (0.24).45 In a 
Cochrane database systemic review of 15 RCTs (n=2,022) 
which included all SGAs and TGAs, ARI was superior to 
HAL which, in turn, was equal to olanzapine and risperidone 
where the risk ratio (RR) was 1.45 (95% CI: 1.22–1.73).46 In a 
meta-analysis by Perlis et al47 (n=4,304) of 12 PLB-controlled 
R
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monotherapy and 6 PLB-controlled adjunctive therapy trials, 
ARI, olanzapine, quetiapine, risperidone, and ziprasidone 
were equally effective against acute mania.47 These find-
ings have been replicated by another meta-analytic study 
that excluded some studies in terms of effect sizes and the 
extracted data.48 A meta-analysis of 13 PLB-controlled RCTs 
of 3,089 subjects including two ARI studies showed an RR of 
1.74 (95% CI: 1.54–1.96) for ARI versus PLB.49 In a post hoc 
analysis based on two 3-week PLB-controlled trials of ARI 
in acute mania,27,28 subjects were classified as having either 
high or low scores of agitation at baseline. In highly agitated 
patients receiving ARI, PANSS-Excited Component (PEC) 
scores were significantly decreased versus PLB at endpoint. 
In patients with low agitation receiving ARI, no increases in 
PEC scores were seen, and a significant reduction in agitation 
symptoms was apparent after adjustment for baseline PEC 
scores. ARI-treated subjects had significantly greater reduc-
tion from baseline in YMRS total scores than PLB-treated 
subjects in both the high and low agitation groups (P,0.05 
for both groups) and significantly improved Clinical Global 
Impression-Bipolar (CGI-BP) scores at endpoint in both 
(P,0.05).50 A recent meta-analysis by Yildiz et al51 of studies 
in acute mania/mixed states of bipolar I (38 studies   involving 
10,800 patients allowing 56 drug–PLB comparisons of 17 
different agents) showed that 13 drugs (76%) were more 
effective than PLB with a pooled effect size of 0.42 (95% 
CI: 0.36–0.48). The NNT for ARI was 6.51 Another recent 
analysis to ascertain the efficacy of SGAs and TGAs either 
as mono and/or adjunctive therapy in mixed episodes of BD 
included 9 RCTs with 1,289 mixed episode patients. This 
showed SGAs and TGAs to be equally effective, with com-
bined effect sizes of 0.56 for pure manic episode and 0.44 
for mixed episodes.52 A review of 24 studies (n=6,187) of 
antipsychotic agents in the treatment of bipolar mania, came 
to the conclusion of the superior efficacy of ARI, amisulpride, 
clozapine, olanzapine, quetiapine, risperidone, ziprasidone, 
and zotepine, either in monotherapy or in combination with 
MS. Importantly, based on their review, the authors concluded 
that adding an antipsychotic to an MS was the most effica-
cious pharmacological treatment for acute mania.53
Depot
So far, data on ARI as an IM depot in BD have not been 
published. A recent large trial evaluated 576 schizophrenic 
subjects that entered IM-depot stabilization treatment after 
initial oral use of medication. Time to impending relapse 
Table 2 Short- and long-term tolerability and safety of ARi in adults
Study AEs $5% and $twice as frequent as with PLB Discontinuation due to AE Reports on severe AEs
Acute mania studies
Keck et al28 ARi 30 mg/day: nausea (23%), dyspepsia (22%),  
somnolence (20%), vomiting (16%), constipation (13%), 
accidental injury (12%), akathisia (11%)
6% for ARi 30 mg/day,  
5% for PLB
ARi 30 mg/day: 4 subjects 
PLB: 4 subjects
Sachs et al27 ARi 30 mg/day: akathisia (18%), dyspepsia (15%),  
constipation (12%)
9% for ARi 30 mg/day,  
8% for PLB
ARi 30 mg/day: 12 subjects 
PLB: 10 subjects
el-Mallakh et al29 ARi 15 mg/day: akathisia (14%), vomiting (11%),  
pain extremity (8%) 
ARi 30 mg/day: akathisia (11%), pain extremity (10%), 
vomiting (5%)
7% for ARi 30 mg/day,  
15% for ARi 15 mg/day,  
7% for PLB
ARi 30 mg/day: 8 subjects 
ARi 15 mg/day: 11 subjects 
PLB: 10 subjects
Kanba et al26 ARi 24 mg/day: akathisia (22%), vomiting (12%),  
tremor (12%), nausea (8%), salivary hypersecretion 
(7%), blood creatine phosphokinase increased (7%)
9% for ARi 24 mg/day,  
9% for PLB
ARi 24 mg/day: 5 subjects 
PLB: 9 subjects
Maintenance studies
Keck et al (26 weeks)42 ARi 15–30 mg/day: tremor (9%), akathisia (7%),  
vaginitis (6%), pain in extremities (5%). 
weight gain $7% of BL weight: 13% of ARi  
subjects, 0% of PLB subjects
19% for ARi 15–30 mg/day, 
10% for PLB
ARi 15–30 mg/day:  
6 subjects 
PLB: 11 subjects
Keck et al (extension  
to 100 weeks)43,*
ARi 15–30 mg/day: tremor (9%), akathisia (8%),  
hypertension (8%), dry mouth (8%), weight gain (7%), 
vaginitis (6%), abnormal thinking (5%), pharyngitis (5%),  
flu syndrome (5%) 
weight gain $7% of BL weight: 20% of ARi subjects,  
5% of PLB subjects
28% for ARi 15–30 mg/day, 
16% for PLB
ARi 15–30 mg/day:  
9 subjects 
PLB: 19 subjects
Notes: Data from selected short- and long-term PLB-controlled studies; *numbers reported in the 100-week extension study are cumulative numbers, also including the 
figures reported for 26 weeks.
Abbreviations: Ae, adverse events; ARi, aripiprazole; BL, baseline; PLB, placebo.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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was significantly delayed with ARI-IM-depot treatment 
compared with PLB in both the interim analysis and the final 
analysis (P,0.0001, log-rank test). ARI depot was safe and 
well tolerated in this study, which should encourage similar 
maintenance studies in BD.54
Current guidelines
Updated guidelines by the World Federation of Societies 
of Biological Psychiatry (WFSBP) for acute mania used 
six categories (A–F) based on levels of evidence for the 
scientific rigor of the literature. ARI was labeled A, ie, the 
highest category of efficacy for acute manic and mixed 
states. Also, given its superior tolerability profile, the highest 
recommendation grade of “1” was granted. Risperidone and 
VAL have also been given similar high ratings.4 Given that 
ARI has well-proven efficacy in relapse prevention of mania 
in patients with index episode of mania that responded to 
ARI, a recommendation grade of “1” was given for its lon-
ger term use.5 A 2012 UK panel consensus on the initiation 
of ARI for the treatment of acute mania agreed that ARI is 
effective both in the short- and long-term treatment of bipo-
lar mania, either as monotherapy or in combination with an 
MS. Unlike other atypical agents, ARI has anti-manic effects 
that are not associated with sedation, and therefore may be 
more beneficial for selected patients, particularly in the long 
term. If rapid tranquillization is required when initiating 
ARI in acutely disturbed patients, short-term coprescription 
of a benzodiazepine is recommended.55 A 2013 update of 
the Canadian Network for Mood and Anxiety Treatments 
  (CANMAT) guidelines for the management of patients with 
bipolar disorder recommends ARI as the first-line option 
for the treatment of acute mania either as monotherapy or 
as adjunctive therapy with LI or divalproex.56 The British 
  Association of Psychopharmacology recommends oral 
administration of antipsychotic or VAL for patients not 
already on long-term treatment for BD because of their rapid 
anti-manic effects compared to LI. ARI is included in their 
recommendations as one of the atypicals with level 1 (highest 
grade) evidence for its effects in acute mania and mixed 
episodes.57 A critical review by an Italian group evaluating 
various trials and other evidence for the role of ARI in acute 
mania and long-term treatment of BD has shown ARI to be 
clinically effective in terms of response rates, remission rates, 
and prevention of relapse. They concluded that the efficacy 
and favorable metabolic profile of ARI make it a good option 
in the management of  acute mania and maintenance treat-
ment,  with the added benefit of better treatment adherence 
rates, especially in an outpatient setting.58
Tolerability
A recent review pointed out ARI’s favorable safety and toler-
ability profile, and minimal propensity for clinically significant 
weight gain and metabolic changes. EPSEs, however, may limit 
treatment in some cases.22 The most   commonly reported adverse 
events (AEs) with ARI occurring in PLB-controlled trials are 
akathisia and nausea, each in .3% of patients treated with 
oral ARI.59 The most common AEs that were considered to 
be treatment related and occurred twice as   frequently in ARI 
compared to PLB during 3-week   monotherapy were akathisia 
(13% vs 4%), sedation (8% vs 3%), restlessness (6% vs 3%), 
tremor (6% vs 3%), and EPSEs (5% vs 2%).   During 6 weeks 
of adjunctive therapy to MS, akathisia (19% vs 5%), insomnia 
(8% vs 4%), and EPSEs (5% vs 1%) were most frequent.12 Two 
recurrence   prevention trials for 5239 or 10043 weeks showed 
tremor, akathisia, hypertension, and dry mouth to be common 
side effects.
In a subgroup analysis of patients receiving adjunctive 
therapy, the most common treatment-emergent AE in ARI 
Table 3 indicators for the use of ARi in bipolar mania
Nature of disorder Patient groups Poor tolerability due to the following 
treatment-emergent side effects
When to consider ARI in acute mania
•    Acute mania with mixed or psychotic episodes
•    New onset and recurrent manic episodes
•    Manic polarity of illness with a view on  
continuation treatment
•    Switch option in subacute mania when  
considering long-term treatment
•    Adjuvant treatment in cases of suboptimal  
response to monotherapy with MS
•    Patients with need for rapid control of  
acute manic or mixed symptoms*
•    Patient choice**
•    Previous response to ARi
•    Overweight and obese subjects
•    High-risk group for metabolic syndrome,  
eg, past history or family history
•    Patients with difficulties in adherence***
•    Sedation
•    Patients prone to weight gain
•    Hyperprolactinemia
•    Cognitive problems
•    Dyslipidemia and metabolic disturbances
•    Sensitivity to manifest ePSes especially 
tardive dyskinesia
•    QTc prolongation
Notes: *Consideration to the IM preparation should be given; **given the unique mode of action and significant differences in side-effect profile compared to other existing 
anti-manic treatments, introducing patients to choices of agents could lead to better treatment adherence; ***the long half-life of the oral formulation and availability of an 
iM depot makes it easier to maintain therapeutic serum levels.
Abbreviations: ARi, aripiprazole; ePSe, extrapyramidal side effects; iM, intramuscular; MS, mood stabilizers.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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plus LI versus ARI plus VAL groups were tremor (17% vs 
12.1%), gastrointestinal side effects (10.4% vs 12.6%), 
weight gain (11.3% vs 8.6%), insomnia (9.4% vs 10.3%), 
depression (7.5% vs 9.2%), akathisia (6.6% vs 8.6%), and 
headache (6.6% vs 4.0%). In the 100-week ARI monotherapy 
trial, approximately twice as many subjects on PLB as on 
ARI had serious treatment-emergent AEs (23% vs 12%) or 
withdrew from therapy because of treatment-emergent AEs 
(28% vs 16%). This was largely due to worsening of manic 
or depressive symptoms in PLB recipients.43 Across all trials, 
the most common treatment-emergent AEs that led to treat-
ment discontinuation in ARI recipients were mania in 1%39 
or manic reaction in 7% of patients,43 akathisia in 5%,12,19 
and tremor in 2%.60
Extrapyramidal side effects
EPSEs are dose related and occurred more often in ARI than 
PLB groups in both monotherapy and adjunctive therapy 
  trials. The majority of AEs in ARI recipients were of mild or 
moderate severity during short-term monotherapy.27,28 There 
were no differences in symptom severity in the longer term 
monotherapy43 or adjunctive therapy.39 Pooled analysis of 
five 3-week monotherapy trials of ARI vs PLB showed no 
difference in EPS-related AEs when akathisia is excluded 
(9% ARI vs 7% PLB); however, AE rates for akathisia just by 
itself were 18% for ARI and 5% for PLB.60 Adjunctive treat-
ment with ARI was also associated with a higher incidence 
of EPSE-related AEs compared to PLB recipients (28.1% 
vs 13.8%). Of these, akathisia (18.6% vs 5.4%) and tremor 
(9.1% vs 6.2%) were the most common AEs.37 Akathisia was 
generally mild or moderate with withdrawal rates of 2.3% 
versus 0% in ARI versus PLB groups in 3-week short-term 
therapy60 and 5.1% versus 0.8% during 6-week adjunctive 
therapy.37 The onset of akathisia was usually during the early 
treatment phase with half of cases resolving by the end of 
study in 3-week trials60 and one-third of cases resolving 
in 6-week trials.37   Comparison of EPSEs during the first 3 
weeks of a 12-week trial comparing ARI with LI showed 23% 
versus 15% occurrence of these AEs. Akathisia was reported 
in 14.9% in ARI-treated patients, usually within the 3-week 
period.33 Akathisia (3.2%) was the most common cause for 
treatment discontinuation in the ARI patients;19 however, 
only two patients in a 100-week monotherapy trial43 and two 
patients in 46-week extension of adjunctive trial40 discontin-
ued because of akathisia.
Weight changes
In short-term trials of a 12-week treatment period, there 
were no statistically significant differences in body weight 
between the ARI and LI (1.4 vs 0.3 kg)33 or HAL groups 
(0.7 vs 0.56 kg)32 and (0.27 vs −0.10 kg),34 respectively. 
Generally, in most BD trials for maintenance either as 
monotherapy or adjuvant therapy, the mean body weight 
increased by 0.1–2.1 kg in ARI recipients versus –1.9 to 
+0.6 kg in PLB recipients. There were no statistically sig-
nificant changes in mean body weight from baseline.12,61 In 
a study of ARI as adjunctive to MS (LI or VAL) versus MS 
alone, there were no significant differences noticed with 
regards to weight gain (+0.55 kg vs +0.23 kg).37 However, 
during the 100-week maintenance phase of a recurrence 
prevention study of ARI monotherapy, significantly 
(P=0.01) more ARI than PLB recipients had a clinically 
significant increase in body weight (20% vs 5%). Interest-
ingly, further analysis of mean weight change in this study 
by body mass index (BMI) at baseline showed no significant 
difference in weight change observed between ARI and 
PLB for patients in both the low baseline BMI (#23 kg/m2) 
and high baseline BMI ($27 kg/m2) categories at study 
endpoint.43 However, a non-randomized trial of SGAs 
and TGAs in a juvenile cohort with a median duration 
of 10.8 weeks of treatment found a higher than expected 
weight gain for most atypicals. A 4.4 kg mean increase of 
body weight was associated with ARI (n=41) compared 
to 0.2 kg in the untreated group (n=15).62 Table 2 depicts 
the tolerability and safety profile of ARI as observed in 
selected short- and long-term studies.
Metabolic effects
A metabolic syndrome (dyslipidemia, insulin-resistant dia-
betes, obesity, and hypertension) occurs at a significantly 
higher incidence in BD than in the general population.63 
ARI is associated with a lower risk of metabolic and cardiac 
issues such as weight gain, diabetes, and dyslipidemia than 
most SGAs.64 In fact, a post hoc analysis of a 26-week study 
showed rates of metabolic syndrome with ARI comparable to 
PLB in patients with BD.65 There were no significant negative 
effects on metabolic parameters, ie, cholesterol, triglycerides, 
or glucose either in short term or long term in trials of ARI 
as monotherapy or in combination with LI or VAL.37,40,43 ARI 
is generally not associated with raised prolactin levels; there-
fore, chances of sexual dysfunction caused by this mechanism 
are low. ARI monotherapy may even be associated with a 
mean decrease in serum prolactin levels in patients coming 
off other antipsychotics.61 Two 3-week trials showed that 
the proportion of patients with mean serum prolactin levels 
above the upper limit of normal were actually lower in the 
ARI monotherapy than in the PLB group (11% vs 17%);28 
(4% vs 11%).27 The ARI group also showed lower increases Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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in prolactin levels in the 12-week trials when compared with 
HAL (22.4% vs 66.2%).32
Cardiovascular morbidity and mortality is of great con-
cern in bipolar patients.66 The use of ARI is considered a 
safe option in patients at risk. The metabolic profile detailed 
above appears benign, and the use of ARI in BD, especially 
in comparison with SGAs, did not raise any safety concerns 
as far as QTc prolongation is concerned.22,61
When to start aripiprazole  
in bipolar mania
Most of the current guidelines recommend the use of atypical 
antipsychotics for the treatment of manic symptoms.4,5,55–58 
However, at least in the UK, ARI appeared to be used rela-
tively infrequently as a first-line treatment for a long time. 
Besides pricing issues, this may be due to its non-sedative 
pharmacological profile and the perceived risks associated 
with treatment-emergent akathisia and EPSE symptoms. 
This may perhaps have led to an underuse of this effective 
treatment option despite its established efficacy in the trials, 
with a subsequent lack of clinical experience, and therefore, 
impacting confidence levels of prescribers to initiate anti-
manic treatment with ARI.
Well-powered trials evaluating its efficacy against PLB 
showed clear and continued separation in YMRS scores from 
day 2–4 onwards.26–28 The current evidence base supports its 
use in acute treatments from day 1 of an acute manic or mixed 
episode with good chances of timely response and remission. 
It is important to note that it also improves the depressive 
component of mixed episodes and not only the manic.44 This 
latter observation makes ARI a good first choice concerning 
the treatment of mixed episodes.
ARI should be considered as the first-choice agent in 
patients with obesity or metabolic disturbances, hyperpro-
lactinemia, QTc prolongation, sensitivity to manifest EPSE, 
and especially tardive dyskinesia, or any other tendency to 
experience specific side effects caused by other SGAs (eg, 
sedation, cognitive disorder, etc). As obesity once manifest is 
difficult to combat and often irreversible, it may also be fea-
sible to use ARI as a first-choice antipsychotic in patients only 
at risk of obesity, whether through lifestyle or genetic predis-
position. Given the low propensity for ARI to cause sedation 
in the longer term, it is less likely to interfere with patients’ 
cognition and level of functioning or quality of life.
As the choice of initial treatment of mania should already 
take continuity of treatment and long-term goals and out-
comes into consideration,67 the most feasible time to initiate 
ARI is right at the acute episode and as early as possible in 
the course of BD.
IM injection of ARI may be considered in special circum-
stances, eg, in patients with high levels of agitation and lack 
of insight. If sedation is needed at this time, additional short-
term benzodiazepine treatment can be added and withdrawn 
as soon as possible.
Potential predictors for ARI response could be previous 
response and/or a manic polarity of the illness and the pres-
ence of mixed features.68 ARI should be considered as a pos-
sible switch option during the subacute phase of mania and 
the continuation treatment if the initial medication has a high 
side-effect burden, especially unwanted sedation or metabolic 
issues. Slow cross-tapering is advised in this case. Using ARI 
as a primary prophylactic agent in euthymic, medication-free 
BD patients has not been studied so far. It may be considered in 
special cases, but is not backed up by evidence, eg, comparable 
to what is known for LI. Table 3 briefly summarizes when ARI 
could be considered as antimanic treatment of choice.
Conclusion
ARI has been shown to be both safe and effective in the treat-
ment of acute manic and mixed episodes in acute and continu-
ation stages of treatment. It also shows similar efficacy and a 
superior tolerability profile when compared against previously 
well-established treatments for acute mania.33,35,38–40 Given the 
lack of significant sedation, the addition of benzodiazepines can 
be considered in the first few days of treatment. ARI also has 
good quality evidence of its efficacy in the continuation and 
early maintenance phases of treatment for patients who have 
responded and been stabilized in the first few weeks of treat-
ment. Overall, ARI is generally well tolerated. Akathisia, tremor, 
headache, dizziness, somnolence, sedation, fatigue, nausea, 
vomiting, and insomnia are some of the common side effects 
in the short term.37,43,59 These side effects, however, appear to be 
tolerable to most patients given the superior continuation rates 
of ARI versus PLB treatment,28,29 and equal or better tolerability 
profile compared to other active treatments.33,38,39 However, 
akathisia is a treatment-emergent side effect that is known to 
contribute to early treatment discontinuation in some patients.60 
ARI has a superior side-effect profile in terms of sedation and 
weight gain, especially compared to well-established treatments 
like LI, VAL, and also most of the atypical antipsychotics. 
With its lower incidence of dyslipidemia, treatment-emergent 
diabetic symptoms, and changes of prolactin levels,37,43,63–65 ARI 
is a safe treatment choice given the need to continue effective 
drug treatments in BD in the long term.
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